Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen

This study investigates the predicting factors of the biochemical response and survival of patients with advanced metastatic prostate cancer who underwent therapy with radioligand lutetium-177 ((177)Lu)-prostate-specific membrane antigen (PSMA), often referred to as [(177)Lu]Lu-PSMA. This study is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathore, Rajni, Rangrej, Shahid B, Kieme, Ian, Carvalho, Victoria, King, Katie, Amadou, Yacoubou, McKinley, John, Masawi, Audrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195000/
https://www.ncbi.nlm.nih.gov/pubmed/37214073
http://dx.doi.org/10.7759/cureus.37778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195000/
https://www.ncbi.nlm.nih.gov/pubmed/37214073
http://dx.doi.org/10.7759/cureus.37778

Ejemplares similares